The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Tarextumab in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Eileen M. O’Reilly, MD
Published Online:6:15 PM, Mon January 23, 2017

Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, and professor of medicine, Weill Cornell Medicine, discusses results of a randomized phase II trial of tarextumab in combination with nab-paclitaxel and gemcitabine in patients with untreated metastatic pancreatic cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.